It is largely recognized that proNGF, the NGF precursor, could represent a promising diagnostic biomarker for AD (Pentz et al., 2020), for the onset of prodromal AD (Counts et al., 2016) or for other neurodegenerative diseases (Belrose et al., 2014; Xu et al., 2018; Pentz et al., 2021), but almost nothing is known concerning its potential relationship to FTD. The gene discussed is NGF; the disease is Alzheimer disease.